Contact us - more seroquel resources seroquel - manufacturer's site providing consumer and professional information on quetiapine fumarate, used for schizophrenia treatment. By the new generation extraction column biotrap 500 ms ; general methods can be used for the extraction of basic and acidic drugs, for example, quetiapine fumarate side effects.

Quetiapine may cause liver damage. Equally well on positive symptoms, and have a documented advantage in relieving negative symptoms. It remains to be seen whether the new medicines are better for cognitive symptoms, such as memory loss and concentration problems. The second-generation antipsychotic, clozapine, was developed to act on a variety of neurotransmitter receptors. Risperidone was developed specifically to block serotonin and dopamine receptors equally. Olanzapine and quetiapine were developed to act like clozapine. Because they are less potent at the dopamine receptor, they tend to have fewer side effects associated with the blockage of dopamine, e.g., tremor, stiff muscles, and agitation. Unfortunately, they have their own undesirable effects, such as a tendency to gain weight. This can be more of a health hazard than stiffness and tremors. There are many kinds of antipsychotic medicines in common use. Each drug has several names: the generic or chemical name first column below ; , and the brand name used by the pharmaceutical companies that manufacture it second column below ; . The table below lists the antipsychotic medicines most commonly used in Canada. Older 1st CHLORPROMAZINE Largactil generation FLUPENTHIXOL Fluanxol antipsychotics ; FLUPHENAZINE Modecate ZUCLOPENTHIXOL Clopixol LOXAPINE Loxapac HALOPERIDOL Haldol PIMOZIDE Orap THIORIDAZINE Mellaril TRIFLUOPERAZINE Stelazine METHOTRIMEPRAZINE Nozinan Newer 2nd CLOZAPINE Clozaril generation OLANZAPINE Zyprexa antipsychotics ; RISPERIDONE Risperdal QUETIAPINE Seroquel and seroquel. A few final thoughts It's important not to think of yourself as a failure simply because one medication alone is not effective for you. Medications affect people differently. Your ultimate goal is to control diabetes as well as possible so that you can enjoy good health.

Quetiapine xl uk Cns drugs 4 1: 66-7 gefvert, o, bergstrom, m, langstrom, b, lundberg, t, lindstrom, l, yates, 1998 ; time course of central nervous dopamine-d 2 and 5-ht 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine ‘ seroquel’ seroquel ; in patients with schizophrenia and quinine. Code Current Narrative N376 Subscriber patient is assigned to active military duty, therefore primary coverage may be TRICARE. Note: New Code 12 1 06 ; N377 Payment adjusted based on a processed replacement claim. Note: New Code 12 1 06 ; N378 Missing incomplete invalid prescription quantity. Note: New Code 12 1 06 ; N379 Claim level information does not match line level information. Note: New Code 12 1 06 ; Modified Codes Code Current Narrative M143 N181 N361 The provider must update license information with the payer. Note: Modified 12 1 06 ; Additional information is required from another provider involved in this service. Note: New Code 2 28 03. Modified 12 1 06 ; Payment adjusted based on multiple diagnostic imaging procedure rules Note: New Code 11 18 05. Modified 12 1 06 ; There are NO deactivated codes NOTE II: Some remark codes may provide information that may not necessarily supplement the explanation provided through a reason code and in some cases another other remark code s ; for an adjustment. Newly created informational codes will have "Alert" in the text to identify them as informational rather than explanatory codes. An example of an informational code: N369 Alert: Although this claim has been processed, it is deficient according to state legislation regulation. The above information is sent per state regulation, but does not explain any adjustment. These informational codes should be used only if specific information needs to be communicated but not as default codes. Medicare Initiated No No No. The newer, atypical neuroleptics on average cost 20 times more per day of therapy than the conventional neuroleptics. Managed care organizations have an interest in determining the value-formoney equation for the atypical neuroleptics. Jeste proposes that this additional cost has been a deterrent to managed care organizations in the prescribing of atypical medications.19 Cost concerns need to be balanced against the risk of potentially serious side effects, especially tardive dyskinesia. Due to the conflicting findings in the literature, the question of whether one drug or a particular class of drugs is associated with a higher risk of tardive dyskinesia remains unanswered. This study examines the difference in risk of tardive dyskinesia associated with the newer, atypical neuroleptic medications compared to the older, conventional neuroleptic medications. Methods Subject Selection This study was a records-based, nested, case-control study of the association between neuroleptic drug use and tardive dyskinesia in a cohort of neuroleptic users at the Veterans Administration Puget Sound Health Care System VA-PSHCS ; between January 1, 1996, and December 31, 1998. The study protocol was approved by the Institutional Review Boards of both the VA-PSHCS and the University of Washington. Electronic pharmacy data were used to identify neuroleptic users and to capture all prescription drugs used by the cohort during the study period Figure 1 ; . Study subjects were active adult 21 years of age ; users of the VA-PSHCS who had received more than one prescription for a neuroleptic medication during the study period. Within this study, the case-defining event was the diagnosis of tardive dyskinesia. Diagnosis of tardive dyskinesia was defined as the presence of the ICD-9 code 333.82 in any hospital discharge diagnosis or clinic visit diagnosis for each subject during the study period. Electronic encounter data were used to identify those subjects with a diagnosis of tardive dyskinesia. Controls were selected at random, using the SPSS 8.0 biostatistical software, 20 from the cohort of neuroleptic users without a diagnosis for tardive dyskinesia. To ensure subjects were active users of the VA-PSHCS, all subjects were required to have had more than one encounter with the VAPSHCS in the period 90 days prior to the first prescription of a neuroleptic medication and in the period 90 days after the last prescription-fill of a neuroleptic medication, or September 30, 1998, whichever came first. Subjects receiving risperidone, olanzapine, quetiapine, or clozapine at any time during the study period were considered users of atypical neuroleptics. Ziprasidone was not available in the U.S. market at the time of this study. Subjects receiving any one of the remaining neuroleptics listed in Table 1 were considered users of conventional neuroleptics. Atypical neuroleptic users were followed from study entry until either a ; they were switched to a and rebetol.

Quetiapine fumarate seroquel dosage SUBJECTS The study included 30 right-handed patients with a DSM-IV diagnosis of either schizophrenia or schizoaffective disorder confirmed using the Structured Clinical Interview for DSM-IV SCID ; , 24 performed by a board-certified research psychiatrist Z.J.D ; . Patients were recruited through the Schizophrenia and Continuing Care Program at the Centre for Addiction and Mental Health Toronto, Ontario ; . Fifteen patients were unmedicated 14 medication-naive and 1 medication-free for longer than 1 year ; and 15 were medicated with either typical or atypical antipsychotic medications 16.86.7 mg of olanzapine, 11 patients; 7 mg of risperidone, 1 patient; 1200 mg of quetiapine, 1 patient; 100 mg of quetiapine + 10 mg of loxapine, 1 patient; and 50 mg of methotrimeprazine + 16 mg of perphenazine, 1 patient ; . The control group consisted of 15 healthy, right-handed volunteers. For all subjects, handedness was confirmed using the Oldfield Handedness Inventory.25 Controls were recruited through advertisements in the community and postings within the hospital. Groups were similar across demographic variables Table 1 ; . Controls were screened for psychopathology with a modified SCID. Exclusion criteria included a self-reported comorbid medical illness or a history of drug or alcohol abuse. The University of Toronto ethics committee approved the study and written informed consent for each participant was obtained. Before the neurophysiologic investigation, we used the Positive and Negative Syndrome Scale PANSS ; to index the severity of psychopathology.26 Most patients scored in the moderate range of symptom severity Table 1 ; . Motor abnormalities were assessed using the Abnormal Involuntary Movements Scale, 27 Simpson-Angus Scale, 28 and Barnes Akathisia Scale.29 None of the subjects demonstrated evidence of motor abnormalities. Expert Consensus Guideline Group. Treatment of schizophrenia. J Clin Psychiatry 1996; 57: 11-58. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. J Psychiatry 1997; 154: 1-63. Lehman AF, Steinwachs DM, and the co-investigators of the PORT Project. Translating research into practice: the schizophrenia patient outcomes research team PORT ; treatment recommendations. Schizophr Bull 1998; 24: 1-10. Pearsall R, Glick ID, Pickar D, Suppes T, Tauscher J, Jobson KO. A new algorithm for treating schizophrenia. Psychopharmacol Bull 1998; 34: 349-53. Nathan PE, Gorman JM. A guide to treatments that work. Oxford: Oxford University Press, 1998. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-51. Kane JM. Schizophrenia: how far have we come? Curr Opin Psychiatry 1999; 12: 17-8. Dixon LB, Lehman AF. Family intervention for schizophrenia. Schizophr Bull 1995; 21: 631-43. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, ris and ribavirin. Of the patients in the CATIE Phase I study, 74% did not stay on their first drug. We offered these patients the opportunity to go into a second phase of the study. An efficacy pathway, or the clozapine pathway, was for patients who didn't have symptom improvement in Phase I. These patients could be randomized to clozapine or to a second-generation drug they didn't get in the first phase, such as olanzapine, quetiapine, or risperidone.

The idd drug delivery systems consist of a micrometer to sub-micrometer sized water-insoluble drug core stabilized with phospholipids with or without other surface modifiers and requip. According to dr, baughman, these studies actually prove that psychiatric drugs cause brain abnormalities since the only individuals with the brain abnormalities are those who have been on the drugs, for example, quetiapine sr. Selected features of new antipsychotic drugs drug dose ; study findings clozapine 200-800mg day ; cochrane effective versus traditional review antipsychotic, fewer antipsychotic drugs 29 studies relapses, greater based 2490 reduction in participants symptoms, fewer drop-outs greater patient satisfaction satisfaction risperidone 2-6mg day ; cochrane effective versus traditional review antipsychotic, antipsychotic drugs 14 studies greater clinical based on 3401 improvement little participants no additional effect positive or negative symptoms, fewer drop-outs olanzapine 10-20mg day ; cochrane effective versus traditional review 5 antipsychotic, fewer antipsychotic drugs studies based drop-outs, lower on 2911 depression scores, participants less sedation, fewer extrapyramidal side effects sertindole 12-20mg day ; randomised effective versus traditional controlled antipsychotic, fewer antipsychotic drugs trials extrapyramidal side effects ziprasidone 80-160mg day ; randomised effective versus traditional controlled antipsychotic, fewer antipsychotic drugs trials extrapyramidal side effects quetiapine 300-450mg day ; cochrane effective versus traditional review antipsychotic, fewer antipsychotic drugs 6 trials extrapyramidal side based on 1417 effects participants drug dose ; selected side effects clozapine 200-800mg day ; sedation, hypersalivation, weight versus traditional gain, increased risk of antipsychotic drugs convulsions at higher doses, 1% risk of agranulocytosis risperidone 2-6mg day ; weight gain, hyperprolactinaemia versus traditional leading to amenorrhoea, antipsychotic drugs galactorrhea, impotence ; , postural hypotension olanzapine 10-20mg day ; sedation, weight gain, dizziness versus traditional antipsychotic drugs sertindole 12-20mg day ; increased risk of qt interval versus traditional prolongation 7% of patients ; antipsychotic drugs ziprasidone 80-160mg day ; sedation versus traditional antipsychotic drugs quetiapine 300-450mg day ; dizziness, dry mouth, sedation versus traditional antipsychotic drugs drug dose ; comments clozapine 200-800mg day ; patients require regular versus traditional haematological monitoring, 31% of antipsychotic drugs patients with schizophrenia previously resistant to drug treatment have clinical improvement risperidone 2-6mg day ; lacks anticholinergic properties, versus traditional patients switched from older antipsychotic drugs antipsychotics which often required the coprescription of anticholinergics to reduce extrapyramidal side effects to risperidone can undergo cholinergic rebound flu-like symptoms ; olanzapine 10-20mg day ; transient elevation of hepatic versus traditional transaminases, lower incidence of antipsychotic drugs tardive dyskinesia compared with haloperidol sertindole 12-20mg day ; baseline and regular ecg monitoring versus traditional recommended, should be avoided in antipsychotic drugs patients taking drugs known to prolong the qt interval, contraindicated in patients with clinically significant cardiovascular disease, now under review because ecg changes noted in some patients ziprasidone 80-160mg day ; weight gain has not been a prominent versus traditional feature of treatment with antipsychotic drugs ziprasidone as compared with clozapine, risperidone, and olanzapine quetiapine 300-450mg day ; high drop-out rates in the trials versus traditional limit interpretation antipsychotic drugs continued abilify clozaril geodon risperdal seroquel zyprexa more on antipsychotic medications recent developments in atypical antipsychotic medications list of antipsychotic medications more on atypical antipsychotics do the new antipsychotics make a difference and ropinirole. Dual localization of H3receptors in the gastric mucosa, namely on the histamine-secreting cell, which is believed to be involved in gastrin stimulationof gastric acid secretion i e . the so-called enterochromaffin-like ECL ; cell ; and on the acidsecreting "parietal" cell itself 27 ; . These studies, however, only rely on pharmacological evidence and do not provide any information on the receptor structure and cellular mechanism of action. In the present work, we have addressed theseaspects using the human gastric tumoral cell line HGTl as cellular model, the analog [3H]N"-MeHAas receptor ligand, and thespecific antagonist thioperamide to carry out receptor affinity purification. The current findings indicate that the HGTl cell contains a H3 receptor biochemically and pharmacologically distinct from the HI and subtypes. The receptor protein has a molecular H, mass of 70 kDa and is negatively coupled to membrane phosphatidylinositol turnover through aso far unidentified G protein sensitive to both cholera and pertussis toxins, for instance, quetiapine 300 mg. Predicting future drug-drug interactions? and tretinoin. Risperidone risperdal ; , olanzapine zyprexa ; , quetiapine seroquel ; , ziprasidone geodon ; and aripiprazole abilify ; are the most used medications from the new generation.

Ther discovery.16 This request was not very precise but, because the Allen Objectors lose on the merits, the issue is moot. B. The Allen Objectors advance two related discovery arguments. They request discovery to explore 1 ; the potential for securing a judgment against AWSC and the Foreign Member Firms and 2 ; the possibility of collusion. The district court did not abuse its discretion in refusing to order discovery on both fronts. "[F]ormal discovery [is not] a necessary ticket to the bargaining table." In re Corrugated Container Antitrust Litig., 643 F.2d 195, 211 5th Cir. Apr. 1981 ; . This court, on several occasions, has rejected precisely the proposition the Allen Objectors propound: that "the settlement process is necessarily inadequate unless informed by the process of discovery." Id. In considering whether a rejection of discovery was an abuse of discretion, we consider whether Objectors' counsel was "groping in the darkness." See Cotton, 559 F.2d at 1332. Generally speaking, a settlement should stand or fall on the adequacy of its terms. See Corrugated Container, 643 F.2d at 211. The overriding theme of our caselaw is that formal discovery is not necessary as long as 1 ; the interests of the class are not prejudiced by the settlement negotiations and 2 ; there are substantial factual bases on which to premise.
The key to accelerate growth in this approximately usd 900 million market will be the results of the initiated phase iii maintenance study, evaluating whether the disease continues being stabilized by zavesca® therapy after a switch from ert in adult patients with stable type 1 gaucher disease and rifater and quetiapine, for example, quetiapine fumarate side effects.
The putative mechanism for serotonin syndrome is of increased brainstem and spinal cord 5-HT 1A ; receptor modulation occurring with 5-HT 2A ; receptor antagonism. It is this synaptic system, which is the association for atypical antipsychotics and serotonin syndrome. In the comparison of atypical antipsychotic medication on the 5-HT 2A ; and 5HT 1A ; systems, quetiapine has theoretically the lowest risk. This is due to significantly less receptor binding, with 100 to 200 times less receptor potency at 5HT 2A ; --compared to risperidone, olanzapine, and clozapine.9 This case report would, however, indicate that even with quetiapine having moderate 5-HT 2A ; receptor antagonism, there is still clinical significance at the upper dose range. Ziprasidone, which has direct 5-HT 1A ; receptor agonism has, conversely, the greatest theoretical potential for serotonin syndrome.
These, particularly parkinsonism, akathisia, sexual dysfunction, sedation and weight gain, are a major cause of non-adherence. Side-effects should be managed by dose reduction preferably ; , a change to a drug with less liability for that specific effect, or the addition of an appropriate antidote. However, in individuals with optimal mental states who adhere to their medication regimen, changing the antipsychotic is not a simple decision. The risks of significant loss of therapeutic response, the emergence of new problematic side-effects and the understandable anxiety of the patient and their carers must be balanced against the benefits accruing from side-effect management. Weight gain and diabetes Weight gain is particularly difficult to address, requiring as it does substantial and permanent dietary and lifestyle changes in a population not known for healthy living. Marked weight gain has been observed with atypical antipsychotics, although it is also a problem with the typicals. Histamine receptor affinity and dopamine affinity relative to 5-HT2 receptors both seem to be robust correlates of weight increase. Low pre-treatment body mass index, young age and female gender increase liability. There are some reports of an association between weight gain and clinical improvement Russell & Mackell, 2001 ; . It remains unclear how much weight gain contributes to type II diabetes and hyperlipidaemia. A large systematic review of weight gain ranked clozapine as presenting the highest risk of gain, followed by olanzapine, quetiapine, risperidone, sertindole, zotepine and amisulpride Taylor & McAskill, 2000 ; . There is no known association yet with aripiprazole. The World Health Organization has estimated that the worldwide prevalence of diabetes will more than double between 1995 and 2025 Buse, 2002 ; . People with schizophrenia are known to have a twoto threefold increased risk for type II diabetes. The strength of the association between antipsychotics and diabetes varies for individual medications, with the largest number of reports for chlorpromazine, clozapine and olanzapine Henderson, 2002 ; . It would seem prudent to monitor patients' weight, glucose and lipid levels, whatever antipsychotic they are prescribed. QTc interval Regarding QTc interval, prolongation greater than 500 ms is a risk factor for torsades de pointes, a potentially fatal ventricular arrhythmia, but is not the direct cause. Olanzapine, quetiapine and risperidone have not been associated with torsades and rifampin. Source: Center for Disease Control and Prevention. Recommendations to improve preconception health and health care--United States: a report of the CDC ATSDR Preconception Care Work Group and the Select panel on Preconception Care. MMWR 2006; 55 No. RR-6 ; : [5].
Drug Clozapine Olanzapine Risperidone Quuetiapine Aripiprazole * Ziprasidone * Weight Gain + + + Risk for Diabetes + + ? Worsens Lipid Profile + + ?. For example, just recently, the food and drug administration approved quetipaine as seroquel to treat both extents of your condition. DESCRIPTION SEROQUEL que6iapine fumarate ; is an antipsychotic drug belonging to a new chemical class, the dibenzothiazepine derivatives. The chemical designation is 2-[2- 4-dibenzo [b, f ] [1, 4]thiazepin-11-yl-1-piperazinyl ; ethoxy]-ethanol fumarate 2: 1 ; salt ; . It is present in tablets as the fumarate salt. All doses and tablet strengths are expressed as milligrams of base, not as fumarate salt. Its molecular formula is C42H50N6O4S2 C4H4O4 and it has a molecular weight of 883.11 fumarate salt ; . The structural formula is.

Eur j clin pharmacol 1981; 19 : 65− 7 article pubmed chemport 18 and seroquel. Establish unresponsiveness. 2 ; Obtain assistance help! activate the EMS. 3 ; Properly position the patient. 4 ; Open the airway. 5 ; Establish breathlessness. 6 ; Ventilate the patient airway obstructed?, Heimlich manoeuvre? ; . 7 ; Establish the presence or absence of a pulse carotid ; . 8 ; Precordial thump? perform closed-chest compressions prn: depth, 0.5 to 1 inch infant ; , 1 to 1.5 inches child ; , or 1.5 to 2 inches adult ; , times 80-100 + minute. Compressions Ventilation ratios 15: 2 or 5: for one or two rescuers, respectively, for adults. 5: 1 for both situations in infants and children. Compression rates 80-100 for children and adults, 100 + for infants. After you stop taking hepsera, your doctor will still need to check your health and take blood tests to check your liver for a few months.
Several other atypical antipsychotics have been developed since clozapine was introduced.The first was risperidone Risperdal ; , followed by olanzapine Zyprexa ; , wuetiapine Seroquel ; , and ziprasidone Geodon ; .Each has a unique side effect profile, but in general, these medications are better tolerated than the earlier drugs. All these medications have their place in the treatment of schizophrenia, and doctors will choose among them. They will consider the person's symptoms, age, weight, and personal and family medication history. Dosages and side effects. Some drugs are very potent and the doctor may prescribe a low dose. Other drugs are not as potent and a higher dose may be prescribed. Unlike some prescription drugs, which must be taken several times during the day, some antipsychotic medications can be taken just once a day. In order to reduce daytime side effects such as sleepiness, some medications can be taken at bedtime. Some antipsychotic medications are available in "depot" forms that can be injected once or twice a month. Most side effects of antipsychotic medications are mild. Many common ones lessen or disappear after the first few weeks of treatment.These include drowsiness, rapid heartbeat, and dizziness when changing position. Some people gain weight while taking medications and need to pay extra attention to diet and exercise to control their weight. Other side effects may include a decrease in sexual ability or interest, problems with menstrual periods, sunburn, or skin rashes. If a side effect occurs, the doctor should be told. He or she may prescribe a different medication, change the dosage or schedule, or prescribe an additional medication to control the side effects. Just as people vary in their responses to antipsychotic medications, they also vary in how quickly they improve. Some symptoms may diminish in days; others take weeks or months. Many people see substantial improvement by the sixth week of treatment. If there is no improvement, the doctor may try a different type of medication. The doctor cannot tell beforehand which medication will work for a person. Sometimes a person must try several medications before finding one that works.

Countries included; belgium, france, germany, italy, netherlands, spain and uk calabrese jr, keck pe jr, macfadden w, et al a randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar i or ii depression.

Janicak PG, Keck PE, Jr., Davis JM, Kasckow JW, Tugrul K, Dowd SM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol. 2001; 21 4 ; : 360-368. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. J Psychiatry 2002; 159 7 ; : 1146-1154. Janicak PG, Bresnahan DB, Sharma R, Davis JM, Comaty JE, Malinick C. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988; 8 1 ; : 33-7. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or in combination for acute mania Cochrane Review ; . In: the Cochrane Library, Issue 1, 2003. Oxford: Update Software. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. A doubleblind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21 4 ; : 389-397. Hirschfeld RM, Keck PE, Jr., Kramer M, Karcher K, Canuso C, Eerdekens M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. J Psychiatry 2004; 161 6 ; : 1057-65. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiap8ne with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6 3 ; : 213-23. Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder Cochrane Review ; . In: The Cochrane Library, Issue 1, 2003 . Oxford: Update Software Fisher C, Broderick W. Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder. Psychiatric Bulletin. 2003; 27: 446-448. Wassef AA, Winkler DE, Roache AL, Abobo VB, Lopez LM, Averill JP, et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasiexperimental clinical trial involving 9, 260 psychiatric admissions. J Psychiatry 2005; 162 2 ; : 330-9. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania.[comment]. British Journal of Psychiatry. 1988; 153: 198-204. Okuma T, Yamashita I, Takahashi R, Itoh H, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry. 1990; 23 3 ; : 143-150. Ortega Soto HA, Hernandez Avila CA, Jasso A, Hasfura Buenaga CA. Carbamazepine vs haloperidol in treatment of manic episodes: a controlled clinical trial. [Spanish]. Salud Mental. 1993; 16 2 ; : 44-50. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry. 2000; 12 1 ; : 5-10. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: A controlled study. J Psychiatry. 2000; 157 3 ; : 463-465. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a doubleblind randomized controlled trial. Int Clin Psychopharmacol. 1999; 14 6 ; : 339-43. Freeman TW, Clothier JL, Pazzaglia PJ, Lesem MD. A double-blind comparison of valproate and lithium in the treatment of acute mania. J Psychiatry. 1992; 149 1 ; : 108-111. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry. 2003; 182 2 ; : 141-147. Bradwejn J, Shriqui CL, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol. 1990; 10 6 ; : 403-408. Edwards R, Stephenson U, Flewett T. Clonazepam in acute mania: A double blind trial. Aust N Z J Psychiatry. 1991; 25 2 ; : 238-242. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. J Clin Psychiatry. 1992; 53 2 ; : 47-52. National Institute for Clinical Excellence. Electroconvulsive Teatment. NICE Technology Appraisal Guidance 59 ; . [cited 11 Feb 2005]. Available from url: : nice page x?o 68305 Angst J. The epidemiology of depressive disorders. Eur Neuropsychopharmacol 1995; 5 Suppl: 95-8. Angst J. Switch from depression to mania: a record study over decades between 1920 and 1982. Psychopathology 1985; 18 2-3 ; : 140-54. Anderson IM. Meta-analytical studies on new antidepressants. British Medical Bulletin 2001; 57: 161-178. Visser HM, Van Der Mast RC, Blom A. Bipolar disorder, antidepressants and induction of hypo ; mania: a systematic review. Tijdschrift voor Psychiatrie 2002; 44 9 ; : 599-608. Various degrees of weight gain have been recognized as a common problem with conventional antipsychotic medications. Weight gain is an important issue in the management of patients, because this adverse effect may be associated with non-compliance and certain medical illnesses, such as diabetes mellitus, cardiovascular disease, certain cancers, and osteoarthritis. Differences have been discovered among secondgeneration antipsychotics with respect to their ability to induce weight gain Table 1-4 ; . A recent meta-analysis, which estimates the weight change after 10 weeks of treatment at a standard dose, demonstrated that mean increases were 4.45 kg for clozapine, 4.15 kg for olanzapine, 2.10 kg for risperidone, and 0.04 kg for ziprasidone. The long-term risk of weight gain with quetiapine appears to be less than that with olanzapine and clozapine. Short-term weight gain 2.16 kg over 10 weeks ; with quetiapine appears comparable to risperidone. Ziprasidone has been associated with minimal weight gain, which could distinguish it among other second-generation antipsychotics. Similarly, aripiprazole appears to cause little or no weight gain. During long-term treatment, clozapine and olanzapine have the largest effects on weight gain; risperidone produces intermediate weight gain; quetiapine and ziprasidone produce the least weight gain. Weight gain does not appear to be dose-dependent, tends to plateau between 6 and 12 months after initiation of treatment, and is mainly due to an increase in body fat. The mechanism by which weight gain occurs during treatment with antipsychotics is poorly understood, but the broader receptor affinities of the agents and their antagonism of histamine H1 and serotonin 5-HT2C receptors have been implicated. There is currently no standard approach to the management of weight gain induced by antipsychotic medication. Patient education prior to initiating treatment should be provided, and regular exercise should be encouraged in all patients receiving antipsychotic medication. Switching to other second-generation antipsychotics with fewer propensities for producing weight gain may be the most efficient way to deal with antipsychotic-induced weight gain.

Table 1. Hemodynamic response to standing. PegIFN + RBV was associated with a higher SVR rate than IFN + RBV. For every 1, 000 patients treated, 607 and 453 patients would be expected to achieve an SVR when treated with PegIFN + RBV and IFN + RBV respectively. Compared with no AVT, the model predicted that the 20-year risk of CHC-related liver disease and death would be reduced by 33% to 36% in relative terms by IFN + RBV and by 45% to 49% by PegIFN + RBV. During patients' lifetimes, compared with no AVT, IFN + RBV was associated with 19 fewer liver transplants and 158 fewer deaths due to liver disease per 1, 000 patients treated. PegIFN + RBV was associated with 26 fewer liver transplants and 212 fewer deaths due to liver disease per 1, 000 patients treated. In terms of risk reduction over 20 years, CHC-related deaths were reduced from 20.1% with no AVT to 13.0% with IFN + RBV and to 10.6% with PegIFN + RBV. The discounted remaining life expectancy for the 43-year-old patient in the analysis was 14.2 years for no AVT, 15.0 years for IFN + RBV, and 15.2 years for PegIFN + RBV Table 2 ; . The discounted remaining!